SCHEMBL2906422

SCHEMBL2906422

CC(C)[C@]1(C(N)=O)C(=O)CCC(=O)N1C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)Cc1ccc2ccccc2c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 4/20 0.44
KISS1R Q969F8 2/20 0.39
MC4R P32245 2/20 0.37
MC3R P41968 2/20 0.37
MC1R Q01726 2/20 0.37
SDCBP O00560 2/20 0.37
SDC2 P34741 2/20 0.37
PSMB8 P28062 1/20 0.37
DPP4 P27487 1/20 0.37
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
MMP9 P14780 3/20 0.35
MMP8 P22894 3/20 0.35
MMP2 P08253 2/20 0.35
CTSC P53634 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901655 0.95 OPRD1 (0.44) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2906563 0.93 OPRD1 (0.41) OPRD1KISS1RMC4RMC3RMC1R
SCHEMBL2901690 0.88 OPRD1 (0.42) OPRD1KISS1RMC4RMC3RMC1R
SCHEMBL2906899 0.88 OPRD1 (0.45) OPRD1KISS1RMC4RMC3RMC1R
SCHEMBL2898235 0.87 PSMB1 (0.46) OPRD1PSMB8MMEACECPA1
SCHEMBL2906420 0.79 OPRD1 (0.48) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2905590 0.77 KISS1R (0.40) OPRD1KISS1RMC4RMC3RMC1R
SCHEMBL2906545 0.77 OPRD1 (0.39) OPRD1KISS1RMC4RMC3RMC1R
SCHEMBL2898823 0.75 MC4R (0.39) MC4RMC3RMC1RPSMB8
SCHEMBL2905764 0.74 OPRD1 (0.36) OPRD1KISS1RMC4RMC3RMC1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239270-A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2010-10-13 EP disclosed
EP-1845106-B1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 EP disclosed
EP-1845106-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2007-10-17 EP disclosed
EP-1157040-B1 LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-22 EP disclosed
US-6365572-B1 FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-02 US disclosed